Breaking News Instant updates and real-time market news.

PGNX

Progenics

$8.86

-0.02 (-0.23%)

16:21
12/22/16
12/22
16:21
12/22/16
16:21

Progenics: Committee recommends continuation of SPECT/CT Phase 3 trial

Progenics Pharmaceuticals announced that its independent Data Monitoring Committee, DMC, has completed review of an interim analysis of the Company's ongoing Phase 3 clinical trial of its PSMA-targeted SPECT/CT imaging agent candidate, 99mTc-MIP-1404, and recommended that the trial continue."The growing acceptance of active surveillance among men with lower-grade prostate cancer presents a significant opportunity for 1404 to enable clinicians and patients to accurately and non-invasively visualize and manage their disease," said Mark Baker, Chief Executive Officer of Progenics. "We are pleased that the DMC has determined that the trial should continue. The decision to undergo more invasive treatments, such as radical prostatectomy, is a difficult one for both patients and their families given the severity of potential side effects, and we look forward to the completion of this study as we work to introduce new and effective surveillance options." This Phase 3 study enrolls patients in the U.S. and Canada with newly-diagnosed or low-grade prostate cancer, whose biopsy indicates a histopathologic Gleason grade of = 3+4 severity and/or are candidates for active surveillance. The study is designed to evaluate the specificity of 1404 imaging to identify patients without clinically significant prostate cancer and sensitivity to identify patients with clinically significant disease. Approximately 190 of a planned 450 patients have been enrolled in the trial to date. A modification to the trial protocol has been proposed by the Company and agreed to by the U.S. Food and Drug Administration (FDA). The change permits patients with low to very low grade prostate cancer to participate in the trial without having to undergo a radical prostatectomy. In these patients, histopathology of tissues obtained from biopsies of those patients (rather than from radical prostatectomies) will be used as the truth standard in determining the specificity and sensitivity of 1404 imaging. The modification of the protocol was proposed in response to a lower percentage of patients enrolled in the trial having clinically insignificant disease, which is likely due to the emerging trend for more men with low-grade disease to use active surveillance for the management of their prostate cancer rather than undergo radical prostatectomy. The Company plans to monitor enrollment of patients based on the prevalence of clinical significant disease before determining whether any adjustment is needed to the sample size of the study. Mr. Baker continued, "Our modification to the protocol reflects emerging trends among men with low grade disease to increasingly favor the use of active surveillance versus more aggressive measures, consistent with treatment guidelines. We believe that this shift underscores the potential for agents such as 1404 to address the growing active surveillance market. In addition, we expect that the protocol modification will allow for a better balance in the enrollment of subjects with clinically significant disease versus those with indolent disease, with the goal of evaluating the specificity of 1404 imaging to identify patients without clinically significant prostate cancer and the sensitivity of 1404 imaging to identify patients with clinically significant disease."

PGNX Progenics
$8.86

-0.02 (-0.23%)

04/05/16
JEFF
04/05/16
NO CHANGE
Target $9
JEFF
Buy
Progenics approvability unchanged by PDUFA delay, says Jefferies
Jefferies analyst Gena Wang believes the approvability of Relistor in opioid-induced constipation is unchanged after the FDA pushed back the drug's action date. She sees a favorable risk/reward for shares of Progenics (PGN) ahead of the PDUFA date and keeps a Buy rating on the shares with a $9 price target. Wang points out that the FDA requested no new data from Progenics partner Valeant (VRX).
06/24/16
06/24/16
NO CHANGE

Needham sees Brexit making EU drug reviews 'less efficient, more expensive'
Needham analyst including Alan Carr, Chad Messer, Danielle Brill and Esther Pang noted that if Article 50 is invoked following the Brexit vote, the European Medicines Agency will need to move out of its current base in London and the U.K. will need to create its own separate regulatory organization for drugs, concluding that Brexit will lead to a "less efficient, more expensive, and potentially lengthier regulatory process" for drug approval in the EU and the U.K. Among the companies that are currently in discussions with the EMA or have drugs under MAA review, Needham lists ACADIA (ACAD) Celator (CPXX), Cempra (CEMP), Gilead (GILD) Intercept (ICPT), Seattle Genetics (SGEN), Valeant (VRX) and Progenics (PGNX).
10/04/16
BMUR
10/04/16
INITIATION
Target $11
BMUR
Buy
Progenics assumed with a Buy at Brean Capital
Brean Capital analyst Jason Wittes assumed coverage of Progenics Pharmaceuticals with a Buy rating and lowered his price target for the shares to $11 from $14.
10/26/16
AGIS
10/26/16
INITIATION
Target $11
AGIS
Buy
Progenics initiated with a Buy at Aegis
Aegis analyst Jason Wittes initiated Progenics with a Buy and a $11 price target.

TODAY'S FREE FLY STORIES

02:45
11/21/17
11/21
02:45
11/21/17
02:45
General news
FX Update: Narrow ranges have been prevailing »

FX Update: Narrow ranges…

SPN

Superior Energy

$8.81

-0.14 (-1.56%)

21:18
11/20/17
11/20
21:18
11/20/17
21:18
Upgrade
Superior Energy rating change at SunTrust »

Superior Energy upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$78.90

-0.59 (-0.74%)

, LOW

Lowe's

$81.46

1.24 (1.55%)

20:25
11/20/17
11/20
20:25
11/20/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MDT

Medtronic

$78.90

-0.59 (-0.74%)

LOW

Lowe's

$81.46

1.24 (1.55%)

ADI

Analog Devices

$93.07

2.65 (2.93%)

DLTR

Dollar Tree

$97.11

2.5 (2.64%)

HRL

Hormel Foods

$33.40

0.28 (0.85%)

CPB

Campbell Soup

$49.93

0.21 (0.42%)

BURL

Burlington Stores

$106.55

1.82 (1.74%)

SIG

Signet Jewelers

$75.84

-0.74 (-0.97%)

DSW

DSW

$22.53

0.38 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 27

    Nov

  • 01

    Dec

  • 07

    Dec

  • 08

    Dec

  • 09

    Jan

CCLP

CSI Compressco

$5.28

-0.16 (-2.94%)

19:32
11/20/17
11/20
19:32
11/20/17
19:32
Hot Stocks
CSI Compressco names Owen Serjeant president »

CSI Compressco announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$57.62

1.13 (2.00%)

, AAPL

Apple

$169.98

-0.17 (-0.10%)

19:04
11/20/17
11/20
19:04
11/20/17
19:04
Periodicals
Applied Materials expected to purchase former Apple complex, Mercury News says »

An office complex that…

AMAT

Applied Materials

$57.62

1.13 (2.00%)

AAPL

Apple

$169.98

-0.17 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

FOX

21st Century Fox

$29.90

-0.58 (-1.90%)

, FOXA

21st Century Fox

$30.66

-0.49 (-1.57%)

18:21
11/20/17
11/20
18:21
11/20/17
18:21
Periodicals
Fox reaches $90M settlement over sexual harassment scandal, Reuters says »

21st Century Fox reached…

FOX

21st Century Fox

$29.90

-0.58 (-1.90%)

FOXA

21st Century Fox

$30.66

-0.49 (-1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$188.00

2.87 (1.55%)

18:19
11/20/17
11/20
18:19
11/20/17
18:19
Hot Stocks
Muddy Waters says Alibaba numbers 'obviously fake' »

Short seller Muddy Waters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

, CHKP

Check Point

$102.98

0.83 (0.81%)

18:15
11/20/17
11/20
18:15
11/20/17
18:15
Recommendations
Palo Alto Networks, Check Point, Fortinet analyst commentary at JPMorgan »

Palo Alto quarter…

PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

CHKP

Check Point

$102.98

0.83 (0.81%)

FTNT

Fortinet

$40.77

0.46 (1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 07

    Dec

  • 11

    Dec

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

AMZN

Amazon.com

$1,126.31

-3.57 (-0.32%)

18:14
11/20/17
11/20
18:14
11/20/17
18:14
Hot Stocks
Amazon announces cloud software for U.S spy agencies AWS Secret Region »

Amazon announced the new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

BIVV

Bioverativ

$50.76

-5.35 (-9.53%)

, RHHBY

Roche

$30.82

1.72 (5.91%)

18:08
11/20/17
11/20
18:08
11/20/17
18:08
Recommendations
Deutsche cuts Bioverativ target to $53 after positive Roche data »

Deutsche Bank analyst…

BIVV

Bioverativ

$50.76

-5.35 (-9.53%)

RHHBY

Roche

$30.82

1.72 (5.91%)

SHPG

Shire

$141.37

-6 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 09

    Dec

  • 23

    Dec

  • 23

    Feb

CUBI

Customers Bancorp

$27.04

0.28 (1.05%)

18:04
11/20/17
11/20
18:04
11/20/17
18:04
Hot Stocks
Customers Bancorp: Flagship could raise capital in IPO transaction in 1H18 »

Customers Bancorp, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

18:04
11/20/17
11/20
18:04
11/20/17
18:04
Hot Stocks
AT&T CEO says has offered DOJ solutions that were not accepted »

Says DOJ suit throws lots…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

NGD

New Gold

$3.21

-0.02 (-0.62%)

18:02
11/20/17
11/20
18:02
11/20/17
18:02
Hot Stocks
New Gold announces sale of Peak Mines for $58M »

New Gold announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMI

Intermolecular

$1.31

0.1 (8.26%)

18:01
11/20/17
11/20
18:01
11/20/17
18:01
Hot Stocks
Intermolecular partners with SITRI to develop MtM technologies »

Intermolecular, Inc and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

CMCSA

Comcast

$35.83

-0.33 (-0.91%)

18:00
11/20/17
11/20
18:00
11/20/17
18:00
Initiation
Comcast initiated at Buckingham »

Comcast initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$51.05

1 (2.00%)

17:59
11/20/17
11/20
17:59
11/20/17
17:59
Hot Stocks
Mellanox up nearly 6% after Starboard discloses a 9.8% stake in the company »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 05

    Dec

  • 06

    Dec

PLNT

Planet Fitness

$30.15

0.07 (0.23%)

17:58
11/20/17
11/20
17:58
11/20/17
17:58
Initiation
Planet Fitness initiated at DA Davidson »

Planet Fitness initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$44.43

0.86 (1.97%)

17:57
11/20/17
11/20
17:57
11/20/17
17:57
Downgrade
Teradyne rating change at Deutsche Bank »

Teradyne downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

CBS

CBS

$55.93

-0.81 (-1.43%)

17:56
11/20/17
11/20
17:56
11/20/17
17:56
Periodicals
CBS News suspends Charlie Rose following sexual harassment claims, AP says 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$55.93

-0.81 (-1.43%)

17:55
11/20/17
11/20
17:55
11/20/17
17:55
Periodicals
Eight women accuse Charlie Rose of sexual harassment, Washington Post says »

Eight women have said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$51.05

1 (2.00%)

, MRVL

Marvell

$21.59

1.3 (6.41%)

17:53
11/20/17
11/20
17:53
11/20/17
17:53
Hot Stocks
Starboard Value reports 9.8% stake in Mellanox, may seek talks »

Peter A. Feld, a…

MLNX

Mellanox

$51.05

1 (2.00%)

MRVL

Marvell

$21.59

1.3 (6.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 05

    Dec

  • 06

    Dec

CDXS

Codexis

17:46
11/20/17
11/20
17:46
11/20/17
17:46
Hot Stocks
Breaking Hot Stocks news story on Codexis »

Telemark Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:45
11/20/17
11/20
17:45
11/20/17
17:45
Hot Stocks
AT&T CEO says giving up control of CNN is a 'non-starter' »

Says plenty of solutions…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

BBY

Best Buy

$56.35

0.52 (0.93%)

17:45
11/20/17
11/20
17:45
11/20/17
17:45
Conference/Events
Best Buy management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:43
11/20/17
11/20
17:43
11/20/17
17:43
Hot Stocks
AT&T CEO says DOJ suit 'defies logic' »

Says has offered…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.